Showing 8761-8770 of 9971 results for "".
- DBV Technologies Presents Breakthrough Data at EAACI-WAO Congresshttps://practicaldermatology.com/news/20130702-dbv_technologies_presents_breakthrough_data_at_eaaci-wao_congress/2459506/DBV Technologies presented six clinical and preclinical presentations on Epicutaneaous Immunotherapy (EPIT) at the European Academy of Allergy & Clinical Immunology & World Allergy Organization & World Allergy & Asthma Congress (EAACI-WAO) in Milan, Italy. DBV's Viaskin technology was highlighted in
- ASDS Launches Cosmetic Dermatology Fellowship Programhttps://practicaldermatology.com/news/20130627-asds_launches_cosmetic_dermatology_fellowship_program/2459508/The American Society for Dermatologic Surgery (ASDS) launched a fellowship accreditation program designed to promote post-residency training in cosmetic dermatologic surgery procedures. According to ASDS President Timothy C. Flynn, MD, fellowship training will give young dermatologists a solid educa
- MiraConnect Lets Candidates Interact with miraDry Treatment Veteranshttps://practicaldermatology.com/news/20130625-miraconnect_lets_candidates_interact_with_miradry_treatment_veterans/2459509/Offering an opportunity for interested to learn more about microwave-based therapy for hyperhidrosis, the miraConnect program from Miramar Labs enables treatment candidates to speak one-on-one with patients who have undergone the procedu
- Viscot Releases Prep-Resistant Ink Markerhttps://practicaldermatology.com/news/20130611-viscot_releases_prep-resistant_ink_marker/2459516/AllSkin Plus+ with Prep Resistant Ink is the first prep-resistant ink marker that offers maximum visibility and prep resistance on all skin tones. Its VIXL brilliant blue ink provides enhanced visibility even after prep and other fluids and remains visible up to 10 times longer than traditional ink.
- National Psoriasis Foundation Awards Research Grantshttps://practicaldermatology.com/news/20130610-national_psoriasis_foundation_awards_research_grants/2459519/Six scientists received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for psoriasis and psoriatic arthritis. Theoharis Theoharides, MD, PhD received a
- Renaissance and GlaxoSmithKline Transfer Nine Productshttps://practicaldermatology.com/news/20130605-renaissance_and_glaxosmithkline_transfer_nine_products/2459522/Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK. The products from GSK and Stiefel, which will be marketed through Renaissance's bran
- Levia Targeted Phototherapy Now Part of Daavlinhttps://practicaldermatology.com/news/20130531-levia_targeted_phototherapy_now_part_of_daavlin/2459525/Daavlin has been appointed by Lerner Medical Devices to exclusively manufacture, sell, and support their Levia Targeted Home Phototherapy Device. The Levia device complements Daavlin's line of home units for the treatment of skin disorders such as psoriasis, vitiligo, and eczema. Product warranties
- New Technical Manager at Jurliquehttps://practicaldermatology.com/news/20130531-new_technical_manager_at_jurlique/2459527/Jurlique appointed Connie Lim to Technical Manager of Global Product Development. In her new role, Ms. Lim will drive innovative formula development, provide technical support, and monitor performance and key milestones in global new product development efforts. Ms. Lim comes to Jurlique with mor
- Two Melanoma Drugs Win FDA Approvalhttps://practicaldermatology.com/news/20130530-two_melanoma_drugs_win_fda_approval/2459528/The FDA approved two new drugs for metastatic or inoperable melanoma, dabrafenib (Tafinlar) and trametinib (Mekinist). Dabrafenib is an inhibitor of the BRAF gene when it carries the so-called V600E mutation. Trametinib inhibits a target known as MEK and is effective primarily against melanomas carr
- Actavis to Acquire Warner Chilcotthttps://practicaldermatology.com/news/20130521-actavis_to_acquire_warner_chilcott/2459533/Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. If successfully completed, the transaction will create a global specialty pharmaceutical company with approximately $11 billion in combined annual revenue, and the third-largest US special